<DOC>
	<DOCNO>NCT02616302</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness treatment daily ( QD ) oral administration dexlansoprazole capsule ( 15 , 30 , 60 mg ) pediatric participant age 1 11 year symptomatic nonerosive gastroesophageal reflux disease ( GERD ) .</brief_summary>
	<brief_title>A Phase 2 Study Dexlansoprazole Delayed-Release Capsules Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease Pediatric Subjects Aged 1 11 Years</brief_title>
	<detailed_description>The drug test study call dexlansoprazole . Dexlansoprazole test treat child age 1 11 year nonerosive gastroesophageal reflux disease ( GERD ) . This study look effectiveness side effect three different dos dexlansoprazole child GERD . The study enroll approximately 80 patient . Participants weigh ≤30 kg randomly assign ( chance , like flip coin ) receive dexlansoprazole 15 30 mg , participant weigh &gt; 30 kg randomize receive dexlansoprazole 30 60 mg. All participant ask take one capsule time day throughout study . Parents/caregivers participant age 1 8 participant age 9 11 ask record time heartburn symptom electronic diary . This multi-center trial conduct worldwide . The overall time participate study 16 week , include 4 week screen study . Participants make multiple visit clinic , plus final phone call 5 10 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>1 . In opinion investigator , participant ( age appropriate ) and/or parent ( ) /legal guardian capable understand comply protocol requirement . 2 . Prior studyspecific procedure perform , informed consent assent form ( applicable ) must sign dated parent ( ) legal guardian participant respectively , appropriate . 3 . Has medical history symptom gastroesophageal reflux disease ( GERD ) least 3 month prior Screening . 4 . Has medical history least 1 fail attempt withdrawal prior proton pump inhibitor ( PPI ) /acid suppressive therapy return symptom upon withdrawal . 5 . Has meet electronic diary ( eDiary ) qualification criterion assess Pediatric Gastroesophageal Reflux Disease Symptom Daily Diaries ( PGSDD ) , define hurt burn stomach , chest , throat least 3 7 consecutive day Screening Period . 6 . Has either ( 1 ) positive endoscopy HetzelDent ( HD ) Grade 1 Histologic Features Reflux Esophagitis ( HFRE ) Scale Grade &lt; 2 , OR ( 2 ) endoscopy HD Grade 0 document pHmetry suggestive acidrelated disease . The pHmetry perform Screening within 6 month sign informed consent assent ( applicable ) GERD symptom . An endoscopy perform within 1 week prior sign inform consent assent ( applicable ) , acceptable replacement screen endoscopy GERD document HD classification scale criterion previously describe , protocolrequired biopsy collect endoscopic picture obtain . 7 . Is male female age 1 11 year inclusive Screening . 1 . Has evidence cardiovascular , pulmonary , central nervous system , hepatic , hematopoietic , renal , metabolic disorder , severe allergy , asthma , allergic skin rash suggest uncontrolled , clinically significant underlying disease condition ( disease study ) , may impact ability participant participate potentially confound study result . 2 . Has coexist disease affect esophagus ( eg , esophageal varix , scleroderma , viral fungal infection , esophageal stricture ) , history radiation therapy cryotherapy esophagus , caustic physiochemical trauma sclerotherapy esophagus . 3 . Has find his/her medical history , physical examination , safety clinical laboratory test give reasonable suspicion underlie disease might interfere conduct trial . 4 . Has history hypersensitivity allergy dexlansoprazole , component dexlansoprazole PPI ( include lansoprazole , omeprazole , rabeprazole , pantoprazole , esomeprazole ) antacid . 5 . Is required take exclude medication anticipate participant require treatment least 1 disallow concomitant medication study evaluation period . 6 . Has condition may require inpatient surgery course study . 7 . Has know history Barrett 's esophagus dysplastic change esophagus . 8 . Has history eosinophilic esophagitis ( EoE ) endoscopic histologic finding suggestive EoE ( &gt; 15 eosinophil per highpowered field [ HPF ] ) 9 . Has history celiac disease , test positive tissue transglutaminase ( tTG ) antibody confirm disease histology . 10 . Has history inflammatory bowel disease , irritable bowel syndrome . 11 . Has active gastric duodenal ulcer within 4 week prior Day 1 . 12 . Requires dilatation esophageal strictures and/or stricture prevent passage endoscope screen endoscopy . Schatzki 's ring ( ring mucosal tissue near low esophageal sphincter ) acceptable . 13 . A female participant reach menarche . 14 . Is know positive human immunodeficiency virus ( HIV ) . 15 . Has current historical evidence ZollingerEllison syndrome hypersecretory condition . 16 . Has history gastric , duodenal , esophageal surgery except simple oversew ulcer . A history gastric tube and/or percutaneous endoscopic gastrostomy ( PEG ) placement allow . 17 . Had acute upper gastrointestinal hemorrhage within 4 week prior endoscopy . 18 . Has donate lose &gt; 10 % total blood volume , undergone plasmapheresis , transfusion blood product within 90 day prior first dose study drug . 19 . Has know history alcohol abuse illegal drug use within past 12 month prior first dose study drug . 20 . Has screen abnormal laboratory value suggest clinically significant underlying disease condition may prevent participant enter study ; participant : creatinine &gt; 1.5 mg/dL , alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal ( ×ULN ) , total bilirubin &gt; 2.0 mg/dL AST/ALT elevate limit normal value . 21 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study may consent assent ( applicable ) duress . Students institution/research facility supervision , subordinate role , investigator also ineligible . 22 . The participant , opinion investigator , unlikely comply protocol unsuitable reason . 23 . Has participate another clinical study and/or receive investigational compound within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>